Intended for healthcare professionals

  1. Research
  2. Randomised double...
  3. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis
Papers

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

BMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7352.1488 (Published 22 June 2002) Cite this as: BMJ 2002;324:1488

Data supplement

  • Criteria for the diagnosis of acute gout

    Table A  Baseline characteristics of participants ...

    Fig A  Schematic representation of patient accounting ...
     

    Criteria for the diagnosis of acute gout

    Clinical diagnosis of acute gout requires criterion A, B, or C to be met

    A. The presence of characteristic urate crystals in the joint fluid (if at past attack then C1 and C4 also)

    B. A tophus proved to contain urate crystals by chemical meansor polarised light microscope and C1 and C4

    C. Presence of six of the following 12 clinical, laboratory, and radiographic phenomena:

    1. Maximum inflammation developed within one day

    2. More than one attack of acute arthritis

    3. Presents with monoarticular arthritis

    4. Redness is observed over the affected joint(s)

    5. First metatarsophalangeal pain or swelling

    6. Unilateral first metatarsophalangeal joint attack

    7. Unilateral tarsal joint attack

    8. Tophus is suspected

    9. Hyperuricaemia

    10. Asymmetric swelling within a joint

    11. Subcortical cysts without erosions in radiograph

    12. Joint fluid culture negative for organisms (Adapted from the 1980 American Rheumatology Association criteria for the classification of acute arthritis of primary gout18)
     
     


     
     

    Table A Baseline characteristics of participants. Values are numbers (percentages) unless stated otherwise

      Characteristic
      Etoricoxib (n=75)
      Indometacin (n=75)
      Mean (SD) age (years)
      48.5 (13.29)
      49.5 (13.71)
      No of men
      73
      69
      Race or ethnic group:
      White
      30 (40.0)
      28 (37.3)
      Black
      5 (6.7)
      7 (9.3)
      Asian
      15 (20.0)
      13 (17.3)
      Hispanic
      18 (24.0)
      17 (22.7)
      Other
      7 (9.3)
      10 (13.3)
      Disease type:
      Monoarticular gout
      46 (61.3)
      53 (70.7)
      Polyarticular gout
      29 (38.7)
      22 (29.3)
      Study joint*:
      Great toe
      25 (33.3)
      30 (40.0)
      Ankle
      19 (25.3)
      13 (17.3)
      Knee
      8 (10.7)
      19 (25.3)
      Other†
      23 (30.6)
      13 (17.3)
      Baseline assessment of pain‡:
      Moderate
      23 (30.7)
      17 (22.7)
      Severe
      39 (52.0)
      44 (58.7)
      Extreme
      12 (16.0)
      14 (18.7)
      Concomitant use of colchicine
      11 (14.7)
      9 (12.0)
      Concomitant use of allopurinol
      12 (16.0)
      14 (18.7)

      *Most painful joint chosen by patient for those with acute polyarticular gout.

      †Most common other joints included tarsus, wrist, and elbow.

      ‡One patient did not have a baseline pain assessment, so pain score collected for total of 74 patients.
       

      Fig A Schematic representation of patient accounting throughout the study.

        *The most common reason for patients not qualifying for randomisation was that they did not meet the diagnostic criteria for acute gouty arthritis or they had laboratory test abnormalities at baseline.

        †Patient withdrew consent, protocol deviation, discontinued for other reasons
         

      Related articles

      See more

      Cited by...

      • Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis
      • The Efficacy and Safety of Treatments for Acute Gout: Results from a Series of Systematic Literature Reviews Including Cochrane Reviews on Intraarticular Glucocorticoids, Colchicine, Nonsteroidal Antiinflammatory Drugs, and Interleukin-1 Inhibitors
      • Outcome Measures in Acute Gout: A Systematic Literature Review
      • Application of the OMERACT Filter to Measures of Core Outcome Domains in Recent Clinical Studies of Acute Gout
      • OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout
      • Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative
      • Gout
      • Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
      • Efficacy and Tolerability of Celecoxib in the Treatment of Acute Gouty Arthritis: A Randomized Controlled Trial
      • Preventing and treating acute gout attacks across the clinical spectrum: A roundtable discussion
      • Progress in Measurement Instruments for Acute and Chronic Gout Studies
      • Serum Urate During Acute Gout
      • A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout
      • Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials
      • EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)
      • Diagnosis and management of gout: a rational approach
      • Gout in primary care
      • Treating acute gouty arthritis with selective COX 2 inhibitors
      Back to top